GLP1R and Alzheimer disease: Moreover, its role in the treatment of AD was further assessed in the phase IIb clinical trial (NCT01843075), where it was assessed as a GLP‐1 analog and showed a notable improvement in cognitive capabilities and MRI volume [116].